Logo image of ISRG

INTUITIVE SURGICAL INC (ISRG) Stock Fundamental Analysis

NASDAQ:ISRG - Nasdaq - US46120E6023 - Common Stock - Currency: USD

488.61  -13.34 (-2.66%)

After market: 490.446 +1.84 (+0.38%)

Fundamental Rating

7

ISRG gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. ISRG scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ISRG is growing strongly while it is still valued neutral. This is a good combination! These ratings could make ISRG a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

ISRG had positive earnings in the past year.
ISRG had a positive operating cash flow in the past year.
Each year in the past 5 years ISRG has been profitable.
ISRG had a positive operating cash flow in each of the past 5 years.
ISRG Yearly Net Income VS EBIT VS OCF VS FCFISRG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

ISRG has a better Return On Assets (12.88%) than 95.19% of its industry peers.
The Return On Equity of ISRG (14.47%) is better than 90.91% of its industry peers.
With an excellent Return On Invested Capital value of 12.59%, ISRG belongs to the best of the industry, outperforming 94.65% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ISRG is above the industry average of 7.91%.
The 3 year average ROIC (12.20%) for ISRG is below the current ROIC(12.59%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.88%
ROE 14.47%
ROIC 12.59%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ISRG Yearly ROA, ROE, ROICISRG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ISRG's Profit Margin of 28.41% is amongst the best of the industry. ISRG outperforms 96.79% of its industry peers.
ISRG's Profit Margin has declined in the last couple of years.
ISRG has a better Operating Margin (28.35%) than 97.33% of its industry peers.
In the last couple of years the Operating Margin of ISRG has declined.
With a decent Gross Margin value of 67.09%, ISRG is doing good in the industry, outperforming 72.19% of the companies in the same industry.
ISRG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.35%
PM (TTM) 28.41%
GM 67.09%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
ISRG Yearly Profit, Operating, Gross MarginsISRG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ISRG is creating some value.
ISRG has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ISRG has more shares outstanding
There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ISRG Yearly Shares OutstandingISRG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ISRG Yearly Total Debt VS Total AssetsISRG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ISRG has an Altman-Z score of 51.48. This indicates that ISRG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 51.48, ISRG belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
ISRG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 51.48
ROIC/WACC1.39
WACC9.04%
ISRG Yearly LT Debt VS Equity VS FCFISRG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

ISRG has a Current Ratio of 4.98. This indicates that ISRG is financially healthy and has no problem in meeting its short term obligations.
ISRG's Current ratio of 4.98 is fine compared to the rest of the industry. ISRG outperforms 74.33% of its industry peers.
A Quick Ratio of 3.97 indicates that ISRG has no problem at all paying its short term obligations.
ISRG's Quick ratio of 3.97 is fine compared to the rest of the industry. ISRG outperforms 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 3.97
ISRG Yearly Current Assets VS Current LiabilitesISRG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

8

3. Growth

3.1 Past

ISRG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.97%, which is quite impressive.
ISRG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.48% yearly.
ISRG shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.77%.
ISRG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.27% yearly.
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%

3.2 Future

Based on estimates for the next years, ISRG will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.45% on average per year.
The Revenue is expected to grow by 14.12% on average over the next years. This is quite good.
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue Next Year18.04%
Revenue Next 2Y16.59%
Revenue Next 3Y16.13%
Revenue Next 5Y14.12%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ISRG Yearly Revenue VS EstimatesISRG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
ISRG Yearly EPS VS EstimatesISRG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 60.70, ISRG can be considered very expensive at the moment.
ISRG's Price/Earnings ratio is a bit cheaper when compared to the industry. ISRG is cheaper than 67.38% of the companies in the same industry.
When comparing the Price/Earnings ratio of ISRG to the average of the S&P500 Index (27.35), we can say ISRG is valued expensively.
The Price/Forward Earnings ratio is 52.97, which means the current valuation is very expensive for ISRG.
Based on the Price/Forward Earnings ratio, ISRG is valued a bit cheaper than the industry average as 66.84% of the companies are valued more expensively.
ISRG is valuated rather expensively when we compare the Price/Forward Earnings ratio to 37.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 60.7
Fwd PE 52.97
ISRG Price Earnings VS Forward Price EarningsISRG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ISRG is valued a bit cheaper than 64.17% of the companies in the same industry.
70.05% of the companies in the same industry are more expensive than ISRG, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 100.34
EV/EBITDA 56.1
ISRG Per share dataISRG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ISRG does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of ISRG may justify a higher PE ratio.
A more expensive valuation may be justified as ISRG's earnings are expected to grow with 13.89% in the coming years.
PEG (NY)6.66
PEG (5Y)5.29
EPS Next 2Y12.18%
EPS Next 3Y13.89%

0

5. Dividend

5.1 Amount

ISRG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

INTUITIVE SURGICAL INC

NASDAQ:ISRG (7/24/2025, 8:00:02 PM)

After market: 490.446 +1.84 (+0.38%)

488.61

-13.34 (-2.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-22 2025-07-22/amc
Earnings (Next)10-15 2025-10-15/amc
Inst Owners88.74%
Inst Owner Change-0.7%
Ins Owners0.45%
Ins Owner Change6.09%
Market Cap175.13B
Analysts78.97
Price Target599.02 (22.6%)
Short Float %1.14%
Short Ratio2.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.91%
Min EPS beat(2)3.05%
Max EPS beat(2)20.76%
EPS beat(4)4
Avg EPS beat(4)11.89%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.01%
EPS beat(12)10
Avg EPS beat(12)4.94%
EPS beat(16)13
Avg EPS beat(16)5.44%
Revenue beat(2)2
Avg Revenue beat(2)3.11%
Min Revenue beat(2)1.09%
Max Revenue beat(2)5.12%
Revenue beat(4)2
Avg Revenue beat(4)1.5%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)3
Avg Revenue beat(8)0.14%
Revenue beat(12)5
Avg Revenue beat(12)-0.1%
Revenue beat(16)7
Avg Revenue beat(16)0.86%
PT rev (1m)0.94%
PT rev (3m)-7.06%
EPS NQ rev (1m)-0.05%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)-2.65%
Revenue NQ rev (1m)0.13%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0.64%
Valuation
Industry RankSector Rank
PE 60.7
Fwd PE 52.97
P/S 20.1
P/FCF 100.34
P/OCF 64.12
P/B 10.24
P/tB 10.46
EV/EBITDA 56.1
EPS(TTM)8.05
EY1.65%
EPS(NY)9.22
Fwd EY1.89%
FCF(TTM)4.87
FCFY1%
OCF(TTM)7.62
OCFY1.56%
SpS24.31
BVpS47.73
TBVpS46.7
PEG (NY)6.66
PEG (5Y)5.29
Profitability
Industry RankSector Rank
ROA 12.88%
ROE 14.47%
ROCE 13.97%
ROIC 12.59%
ROICexc 17.07%
ROICexgc 17.56%
OM 28.35%
PM (TTM) 28.41%
GM 67.09%
FCFM 20.03%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ROICexc(3y)18.44%
ROICexc(5y)19.03%
ROICexgc(3y)19.29%
ROICexgc(5y)20.12%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexcg growth 3Y-7.59%
ROICexcg growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 185.49%
Cap/Sales 11.31%
Interest Coverage 250
Cash Conversion 90.98%
Profit Quality 70.49%
Current Ratio 4.98
Quick Ratio 3.97
Altman-Z 51.48
F-Score6
WACC9.04%
ROIC/WACC1.39
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
Revenue Next Year18.04%
Revenue Next 2Y16.59%
Revenue Next 3Y16.13%
Revenue Next 5Y14.12%
EBIT growth 1Y32.69%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year33.95%
EBIT Next 3Y22.85%
EBIT Next 5Y19.86%
FCF growth 1Y73.18%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y66.62%
OCF growth 3Y4.95%
OCF growth 5Y8.61%